Drugs / EB103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06343311 | Jun 2024 → Dec 2026 expected | HIV-associated cancer, central nervous system non-hodgkin lymphoma, high grade B-cell lymphoma, large B-cell lymphoma | Estrella Biopharma, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-02-09 | Estrella Biopharma, Inc. | Results Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® estrellabio.com ↗
In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated a 100% Complete Response (CR) rate in the high-dose cohort at Month 1. |
| 2025-12-04 | Estrella Biopharma, Inc. | Results Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation estrellabio.com ↗
The high-dose cohort achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients. |
| 2025-11-03 | Estrella Biopharma, Inc. | Results Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients estrellabio.com ↗
The study has achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients treated in the second dose cohort. |
| 2025-02-21 | Estrella Biopharma, Inc. | Results Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort estrellabio.com ↗
Preliminary data from this cohort demonstrated a favorable safety profile, with no dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) observed. |
| 2024-09-27 | Estrella Biopharma, Inc. | Results Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells estrellabio.com ↗
Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06343311 ↗ |
| Modality | Cell therapy | “autologous T-cell therapy” NCT06343311 ↗ |